o steps from 100% to 50% to 0%. Clinical endpoints included asthma control determined by a validated questionnaire (ACQ), lung function objectively assessed by spirometry (FEV1), day and night-time asthma symptoms and use of relief medication. In addition inflammatory markers (exhaled nitric oxide and eosinophils in the peripheral blood) were evaluated. The study met all clinical endpoints. In patients treated with CYT003 their asthma control improved despite ICS withdrawal. In patients on placebo, the withdrawal of ICS, as expected, led to a worsening of the disease with a statistically significant and clinically important difference between treatment groups. Treatment with CYT003 was safe and generally well tolerated.
Cytos' lead candidate CYT003 is a first-in-class immune modulator in clinical development as a potential new treatment for allergic asthma. CYT003 is currently being evaluated in a global, randomized and placebo-controlled Phase 2b clinical trial as an add-on therapy in 360 patients with moderate to severe allergic asthma not sufficiently controlled on standard controller therapy. The study was initiated in Q4 2012 and top-line results are expected in H1 2014.
Cytos has completed a Phase 2a study demonstrating CYT003 maintains asthma control and lung function, despite standard inhaled corticosteroid withdrawal. Its attractive safety profile is further supported by a database of over 450 patients treated with CYT003 in previous studies.
CYT003 acts via a novel mechanism of action to selectively suppress the body's immune response to allergens, which is considered a predominant risk factor for asthma.
About allergic asthma
Asthma is one of the most common chronic diseases, with an estimated 300 million individuals affected worldwide. Its prevalence is increasing, especially among children, with an expected 400 million patients by 2025. Allergic asthma is the most common type of asthma with 75%-85%
Page: 1 2 3 4 5 Related biology news :1
|SOURCE Cytos Biotechnology Ltd|
Copyright©2012 PR Newswire.
All rights reserved
. How plants sense gravity -- a new look at the roles of genetics and the cytoskeleton2
. Frontiers launches new open-access journal in Bioengineering and Biotechnology3
. AAPS announces 2013 National Biotechnology Conference award winners4
. 2013 AAPS National Biotechnology Conference returns to San Diego5
. Governor Corbett Presented 2013 Biotechnology Industry Organization Governor of the Year Award6
. Karl Deisseroth, Gero Miesenböck and Edward Boyden win Brandeis Gabbay Award in Biotechnology7
. Top 10 ways biotechnology could improve our everyday life8
. New Market Forecasts Available for Critical Global Biotechnology Testing and Screening Markets: Molecular Diagnostics, Hematology, Clinical Chemistry and Nucleic Acid Testing9
. Wiley signs collaboration agreement with the Asian Federation of Biotechnology10
. UMN scientists get federal grant for biotechnology development to purify fracking water11
. Biomass characterization technology research highlighted in Industrial Biotechnology journal